Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.

Lead sponsor: Merz Pharmaceuticals GmbH•39 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

COMPLETEDPhase 2

Study of BGG492 in Patients With Chronic Subjective Tinnitus

NCT01302873 · Chronic Subjective Tinnitus

COMPLETEDPhase 3

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus

NCT00739635 · Subjective Tinnitus

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 28, 2012Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment455

Start dateSep 2009

Last updatedNov 28, 2012

Condition

Subjective Tinnitus

Locations shown

Horizon Clinical Research Associates PLLC

Gilbert, Arizona

Phoenix Clinical

Phoenix, Arizona

Paradigm Clinical Research

Tucson, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 28, 2012Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions